I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions

Biological Chemistry
Sibusiso B MasekoJohnson Lin

Abstract

The efficacy of HIV-1 protease (PR) inhibition therapies is often compromised by the emergence of mutations in the PR molecule that reduces the binding affinity of inhibitors while maintaining viable catalytic activity and affinity for natural substrates. In the present study, we used a recombinant HIV-1 C-SA PR and a recently reported variant for inhibition (Ki, IC50) and thermodynamic studies against nine clinically used inhibitors. This is the first time that binding free energies for C-SA PR and the mutant are reported. This variant PR harbours a mutation and insertion (I36T↑T) at position 36 of the C-SA HIV-1 PR, and did not show a significant difference in the catalytic effect of the HIV-1 PR. However, the nine clinically approved HIV PR drugs used in this study demonstrated weaker inhibition and lower binding affinities toward the variant when compared to the wild type HIV-1 PR. All the protease inhibitors (PIs), except Amprenavir and Ritonavir exhibited a significant decrease in binding affinity (p<0.0001). Darunavir and Nelfinavir exhibited the weakest binding affinity, 155- and 95-fold decreases respectively, toward the variant. Vitality values for the variant PR, against the seven selected PIs, confirm the impact of ...Continue Reading

References

Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N E KohlI S Sigal
Feb 3, 2004·Current Drug Targets. Infectious Disorders·Adrian Velazquez-CampoyErnesto Freire
Jul 21, 2004·Journal of Computational Chemistry·Eric F PettersenThomas E Ferrin
Feb 6, 2007·Drug Discovery Today·Viktor Hornak, Carlos Simmerling
Oct 14, 2011·Viruses·Akbar AliCelia A Schiffer
Feb 3, 2012·Journal of the American Chemical Society·Seema MittalCelia A Schiffer
Jul 12, 2013·ISRN Microbiology·Maria Mercedes Santoro, Carlo Federico Perno
Mar 22, 2014·Science·Christophe FraserSebastian Bonhoeffer
Aug 6, 2014·Proceedings of the National Academy of Sciences of the United States of America·Hironori HayashiHiroaki Mitsuya
Oct 23, 2015·Journal of Virology·Crystal L MoyerGlen R Nemerow
Jan 16, 2016·Journal of Peptide Science : an Official Publication of the European Peptide Society·T Amanda StromAndrew R Barron

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
UCSF Chimera

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.